PALB2 and cancer: PALB2 mutations are considered to be actionable, and are a biomarker for response to Poly (ADP-ribose) polymerase (PARP) inhibitors in pancreatic (ClinicalTrials.gov Identifier: NCT03140670) and prostatic (ClinicalTrials.gov Identifier: NCT02952534) cancers.